Skip to main content
Erschienen in: Medical Oncology 2/2012

01.06.2012 | Original Paper

Association of follicular lymphoma risk with BRCA2 N372H Polymorphism in Slovak population

verfasst von: Ján Šalagovič, Lucia Klimčáková, Denisa Ilenčíková, Adriana Kafková

Erschienen in: Medical Oncology | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

Follicular lymphoma (FL) is one of the most common Non-Hodgkin lymphoma (NHL) subtype. Only small number of studies concerning NHL and DNA reparation gene polymorphisms has been performed so far. Hence, we have assessed the effect of 4 selected polymorphisms with possible influence on risk of FL development in a case–control study in Slovak population. We have genotyped polymorphisms in the RAG1 (K820R), LIG4 (T9I), BRCA2 (N372H), and WRN (V114I) genes in 108 patients with histologically proven FL diagnosis and 127 healthy controls. For discrimination between the allelic variants, we have established the genotyping by real-time melting analysis of an unlabeled probe. The most notable finding was related to polymorphism N372H in the BRCA2 gene. Compared with the wild-type genotype (NN), the homozygous variant genotype (HH) was associated with an increased FL risk (OR = 2.91, 95% CI: 0.96–8.81), although on the borderline of statistical significance (P = 0.050). However, after stratification by gender and age, the FL risk was significantly increased in men with variant-containing genotypes (OR = 2.79, 95% CI: 1.20–6.45) and even severalfold significantly increased among men with homozygous variant BRCA2 genotype (OR = 21.18, 95% CI: 2.46–182.2). No significant associations with FL risk were identified for other polymorphisms.
Literatur
1.
Zurück zum Zitat Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917.PubMedCrossRef Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917.PubMedCrossRef
2.
Zurück zum Zitat Hartge P. Estimating the burden of disease and the benefits of prevention. Epidemiology. 2006;17(5):498–9.PubMedCrossRef Hartge P. Estimating the burden of disease and the benefits of prevention. Epidemiology. 2006;17(5):498–9.PubMedCrossRef
3.
Zurück zum Zitat Hartge P, Wang SS. Overview of the etiology and epidemiology of lymphoma. In: Mauch PM, Armitage JO, Coiffier B, Dalla-Favera R, Harris NL, editors. Non-Hodgkin’s Lymphomas. Philadelphia: Lippincott Williams& Wilkins; 2004. p. 711–27. Hartge P, Wang SS. Overview of the etiology and epidemiology of lymphoma. In: Mauch PM, Armitage JO, Coiffier B, Dalla-Favera R, Harris NL, editors. Non-Hodgkin’s Lymphomas. Philadelphia: Lippincott Williams& Wilkins; 2004. p. 711–27.
4.
Zurück zum Zitat Au WY, Gascoyne RD, Klasa RD, et al. Incidence and spectrum of non-Hodgkin lymphoma in Chinese migrants to British Columbia. Br J Haematol. 2005;128:792–6.PubMedCrossRef Au WY, Gascoyne RD, Klasa RD, et al. Incidence and spectrum of non-Hodgkin lymphoma in Chinese migrants to British Columbia. Br J Haematol. 2005;128:792–6.PubMedCrossRef
5.
Zurück zum Zitat Iscovich J, Parkin DM. Risk of cancer in migrants and their descendants in Israel: I. Leukaemias and lymphomas. Int J Cancer. 1997;70:649–53.PubMedCrossRef Iscovich J, Parkin DM. Risk of cancer in migrants and their descendants in Israel: I. Leukaemias and lymphomas. Int J Cancer. 1997;70:649–53.PubMedCrossRef
6.
Zurück zum Zitat Rothman N, Skibola CF, Wang SS, et al. Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol. 2006;7:27–38.PubMedCrossRef Rothman N, Skibola CF, Wang SS, et al. Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol. 2006;7:27–38.PubMedCrossRef
7.
Zurück zum Zitat Wang SS, Slager SL, Brennan P, et al. Family history of hematopoietic malignancies and risk of non-Hodgkin lymphoma (NHL): a pooled analysis of 10 211 cases and 11 905 controls from the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007;109:3479–88.PubMedCrossRef Wang SS, Slager SL, Brennan P, et al. Family history of hematopoietic malignancies and risk of non-Hodgkin lymphoma (NHL): a pooled analysis of 10 211 cases and 11 905 controls from the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007;109:3479–88.PubMedCrossRef
8.
Zurück zum Zitat Kuppers R, Dalla-Favera R. Mechanisms of chromosomal translocations in B cell lymphomas. Oncogene. 2001;20:5580–94.PubMedCrossRef Kuppers R, Dalla-Favera R. Mechanisms of chromosomal translocations in B cell lymphomas. Oncogene. 2001;20:5580–94.PubMedCrossRef
9.
Zurück zum Zitat Dyer MJS. The pathogenetic role of oncogenes deregulated by chromosomal translocation in B-cell malignancies. Int J Hematol. 2003;77:315–20.PubMedCrossRef Dyer MJS. The pathogenetic role of oncogenes deregulated by chromosomal translocation in B-cell malignancies. Int J Hematol. 2003;77:315–20.PubMedCrossRef
10.
11.
Zurück zum Zitat Bende RJ, Smit LA, van Noesel CJM. Molecular pathways in follicular lymphoma. Leukemia. 2006;21:18–29.PubMedCrossRef Bende RJ, Smit LA, van Noesel CJM. Molecular pathways in follicular lymphoma. Leukemia. 2006;21:18–29.PubMedCrossRef
12.
Zurück zum Zitat Hill DA, Wang SS, Cerhan JR, et al. Risk of non-Hodgkin lymphoma (NHL) in relation to germline variation in DNA repair and related genes. Blood. 2006;108:3161–7.PubMedCrossRef Hill DA, Wang SS, Cerhan JR, et al. Risk of non-Hodgkin lymphoma (NHL) in relation to germline variation in DNA repair and related genes. Blood. 2006;108:3161–7.PubMedCrossRef
13.
Zurück zum Zitat Papavasiliou FN, Schatz DG. Cell-cycle-regulated DNA double-stranded breaks in somatic hypermutation of immunoglobulin genes. Nature. 2000;408:216–21.PubMedCrossRef Papavasiliou FN, Schatz DG. Cell-cycle-regulated DNA double-stranded breaks in somatic hypermutation of immunoglobulin genes. Nature. 2000;408:216–21.PubMedCrossRef
14.
Zurück zum Zitat Shen M, Zheng T, Lan Q, Zhang Y, Zahm SH, Wang SS, et al. Polymorphisms in DNA repair genes and risk of non-Hodgkin lymphoma among women in Connecticut. Hum Genet. 2006;119:659–68.PubMedCrossRef Shen M, Zheng T, Lan Q, Zhang Y, Zahm SH, Wang SS, et al. Polymorphisms in DNA repair genes and risk of non-Hodgkin lymphoma among women in Connecticut. Hum Genet. 2006;119:659–68.PubMedCrossRef
15.
Zurück zum Zitat Smedby KE, Lindgren CM, Hjalgrim H, Humphreys K, Schollkopf C, Chang ET, et al. Variation in DNA repair genes ERCC2, XRCC1, and XRCC3 and risk of follicular lymphoma. Cancer Epidemiol Biomarkers Prev. 2006;15:258–65.PubMedCrossRef Smedby KE, Lindgren CM, Hjalgrim H, Humphreys K, Schollkopf C, Chang ET, et al. Variation in DNA repair genes ERCC2, XRCC1, and XRCC3 and risk of follicular lymphoma. Cancer Epidemiol Biomarkers Prev. 2006;15:258–65.PubMedCrossRef
16.
Zurück zum Zitat Wu X, Gu J, Grossman HB, et al. Bladder cancer predisposition: a multigenic approach to DNA-repair and cellcycle-control genes. Am J Hum Genet. 2006;78(3):464–79.PubMedCrossRef Wu X, Gu J, Grossman HB, et al. Bladder cancer predisposition: a multigenic approach to DNA-repair and cellcycle-control genes. Am J Hum Genet. 2006;78(3):464–79.PubMedCrossRef
17.
Zurück zum Zitat Roddam PL, Rollinson S, O’Driscoll M, et al. Genetic variants of NHEJ DNA ligase IV can affect the risk of developing multiple myeloma, a tumour characterised by aberrant class switch recombination. J Med Genet. 2002;39(12):900–5.PubMedCrossRef Roddam PL, Rollinson S, O’Driscoll M, et al. Genetic variants of NHEJ DNA ligase IV can affect the risk of developing multiple myeloma, a tumour characterised by aberrant class switch recombination. J Med Genet. 2002;39(12):900–5.PubMedCrossRef
18.
Zurück zum Zitat Kuschel B, Auranen A, McBride S, et al. Variants in DNA double-strand break repair genes and breast cancer susceptibility. Hum Mol Genet. 2002;11(12):1399–407.PubMedCrossRef Kuschel B, Auranen A, McBride S, et al. Variants in DNA double-strand break repair genes and breast cancer susceptibility. Hum Mol Genet. 2002;11(12):1399–407.PubMedCrossRef
19.
Zurück zum Zitat Figueroa JD, Malats N, Rothman N, et al. Evaluation of genetic variation in the double-strand break repair pathway and bladder cancer risk. Carcinogenesis. 2007;28(8):1788–93.PubMedCrossRef Figueroa JD, Malats N, Rothman N, et al. Evaluation of genetic variation in the double-strand break repair pathway and bladder cancer risk. Carcinogenesis. 2007;28(8):1788–93.PubMedCrossRef
20.
Zurück zum Zitat Palli D, Falchetti M, Masala G, et al. Association between the BRCA2 N372H variant and male breast cancer risk: a population-based case–control study in Tuscany, Central Italy. BMC Cancer. 2007;7:170.PubMedCrossRef Palli D, Falchetti M, Masala G, et al. Association between the BRCA2 N372H variant and male breast cancer risk: a population-based case–control study in Tuscany, Central Italy. BMC Cancer. 2007;7:170.PubMedCrossRef
21.
Zurück zum Zitat Hiom K, Melek M, Gellert M. DNAtransposition by the RAG1 and RAG2 proteins: a possible source of oncogenic translocations. Cell. 1998;94:463–70.PubMedCrossRef Hiom K, Melek M, Gellert M. DNAtransposition by the RAG1 and RAG2 proteins: a possible source of oncogenic translocations. Cell. 1998;94:463–70.PubMedCrossRef
22.
Zurück zum Zitat Corneo B, Moshous D, Gungor T, et al. Identical mutations in RAG1 or RAG2 genes leading to defective V(D)J recombinase activity can cause either T-B-severe combined immune deficiency or Omenn syndrome. Blood. 2001;97:2772–6.PubMedCrossRef Corneo B, Moshous D, Gungor T, et al. Identical mutations in RAG1 or RAG2 genes leading to defective V(D)J recombinase activity can cause either T-B-severe combined immune deficiency or Omenn syndrome. Blood. 2001;97:2772–6.PubMedCrossRef
23.
Zurück zum Zitat Villa A, Sobacchi C, Notarangelo LD, et al. V(D)J recombination defects in lymphocytes due to RAG mutations: severe immunodeficiency with a spectrum of clinical presentations. Blood. 2001;97:81–8.PubMedCrossRef Villa A, Sobacchi C, Notarangelo LD, et al. V(D)J recombination defects in lymphocytes due to RAG mutations: severe immunodeficiency with a spectrum of clinical presentations. Blood. 2001;97:81–8.PubMedCrossRef
24.
Zurück zum Zitat Gao Y, Ferguson DO, Xie W, et al. Interplay of p53 and DNA-repair protein XRCC4 in tumorigenesis, genomic stability and development. Nature. 2000;404:897–900.PubMedCrossRef Gao Y, Ferguson DO, Xie W, et al. Interplay of p53 and DNA-repair protein XRCC4 in tumorigenesis, genomic stability and development. Nature. 2000;404:897–900.PubMedCrossRef
25.
Zurück zum Zitat Healey CS, Dunning AM, Teare MD, et al. A common variant in BRCA2 is associated with both breast cancer risk and prenatal viability. Nat Genet. 2000;26:362–4.PubMedCrossRef Healey CS, Dunning AM, Teare MD, et al. A common variant in BRCA2 is associated with both breast cancer risk and prenatal viability. Nat Genet. 2000;26:362–4.PubMedCrossRef
26.
Zurück zum Zitat Spurdle AB, Hopper JL, Chen X, et al. The BRCA2 372 HH genotype is associated with risk of breast cancer in Australian women under age 60 years. Cancer Epidemiol Biomarkers Prev. 2002;11:413–6.PubMed Spurdle AB, Hopper JL, Chen X, et al. The BRCA2 372 HH genotype is associated with risk of breast cancer in Australian women under age 60 years. Cancer Epidemiol Biomarkers Prev. 2002;11:413–6.PubMed
27.
Zurück zum Zitat Auranen A, Spurdle AB, Chen X, et al. BRCA2 Arg372His polymorphism and epithelial ovarian cancer risk. Int J Cancer. 2003;103:427–30.PubMedCrossRef Auranen A, Spurdle AB, Chen X, et al. BRCA2 Arg372His polymorphism and epithelial ovarian cancer risk. Int J Cancer. 2003;103:427–30.PubMedCrossRef
28.
Zurück zum Zitat Wenham RM, Schildkraut JM, McLean K, et al. Polymorphisms in BRCA1 and BRCA2 and risk of epithelial ovarian cancer. Clin Cancer Res. 2003;9:4396–403.PubMed Wenham RM, Schildkraut JM, McLean K, et al. Polymorphisms in BRCA1 and BRCA2 and risk of epithelial ovarian cancer. Clin Cancer Res. 2003;9:4396–403.PubMed
29.
Zurück zum Zitat Cox DG, Hankinson SE, Hunter DJ. No association between BRCA2 N372H and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2005;14:1353–4.PubMedCrossRef Cox DG, Hankinson SE, Hunter DJ. No association between BRCA2 N372H and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2005;14:1353–4.PubMedCrossRef
30.
Zurück zum Zitat The Breast Cancer Linkage Consortium. Cancer Risks in BRCA2 mutation carriers. J Natl Cancer Inst. 1999;91:1310–6.CrossRef The Breast Cancer Linkage Consortium. Cancer Risks in BRCA2 mutation carriers. J Natl Cancer Inst. 1999;91:1310–6.CrossRef
31.
Zurück zum Zitat Scott K, Adamson PJ, Barrans SL, Worrillow LJ, et al. RAG1 and BRCA2 polymorphisms in non-Hodgkin lymphoma. Blood. 2007;109(12):552–3.CrossRef Scott K, Adamson PJ, Barrans SL, Worrillow LJ, et al. RAG1 and BRCA2 polymorphisms in non-Hodgkin lymphoma. Blood. 2007;109(12):552–3.CrossRef
32.
Zurück zum Zitat Fuks F, Milner J, Kouzarides T. BRCA2 associates with acetyltransferase activity when bound to P/CAF. Oncogene. 1998;17:2531–4.PubMedCrossRef Fuks F, Milner J, Kouzarides T. BRCA2 associates with acetyltransferase activity when bound to P/CAF. Oncogene. 1998;17:2531–4.PubMedCrossRef
33.
Zurück zum Zitat Orwoll E, Lambert LC, Marshall LM, et al. Testosterone and estradiol among older men. J Clin Endocrinol Metab. 2006;91:1336–44.PubMedCrossRef Orwoll E, Lambert LC, Marshall LM, et al. Testosterone and estradiol among older men. J Clin Endocrinol Metab. 2006;91:1336–44.PubMedCrossRef
34.
Zurück zum Zitat Zhoucun A, Zhang S, Yang Y, et al. The common variant N372H in BRCA2 gene may be associated with idiopathic male infertility with azoospermia or severe oligozoospermia. Eur J Obstet Gynecol Reprod Biol. 2006;124:61–4.PubMedCrossRef Zhoucun A, Zhang S, Yang Y, et al. The common variant N372H in BRCA2 gene may be associated with idiopathic male infertility with azoospermia or severe oligozoospermia. Eur J Obstet Gynecol Reprod Biol. 2006;124:61–4.PubMedCrossRef
35.
Zurück zum Zitat Ozgenc A, Loeb LA. Current advances in unraveling the function of the Werner syndrome protein. Mutat Res. 2005;577(1–2):237–51.PubMed Ozgenc A, Loeb LA. Current advances in unraveling the function of the Werner syndrome protein. Mutat Res. 2005;577(1–2):237–51.PubMed
36.
Zurück zum Zitat Goto M, Miller RW, Ishikawa Y, Sugano H. Excess of rare cancers in Werner syndrome. Cancer Epidemiol Biomarkers Prev. 1996;5:239–46.PubMed Goto M, Miller RW, Ishikawa Y, Sugano H. Excess of rare cancers in Werner syndrome. Cancer Epidemiol Biomarkers Prev. 1996;5:239–46.PubMed
Metadaten
Titel
Association of follicular lymphoma risk with BRCA2 N372H Polymorphism in Slovak population
verfasst von
Ján Šalagovič
Lucia Klimčáková
Denisa Ilenčíková
Adriana Kafková
Publikationsdatum
01.06.2012
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 2/2012
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-011-9925-9

Weitere Artikel der Ausgabe 2/2012

Medical Oncology 2/2012 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.